Results 221 to 230 of about 25,894 (252)
Some of the next articles are maybe not open access.
Network‐Based Approaches for Drug Repositioning
Molecular Informatics, 2021AbstractWith deep learning creeping up into the ranks of big data, new models based on deep learning and massive data have made great leaps forward rapidly in the field of drug repositioning. However, there is no relevant review to summarize the transformations and development process of models and their data in the field of drug repositioning.
Tao Song +5 more
openaire +2 more sources
Current status of drug repositioning in hematology
Expert Review of Hematology, 2021Drug repositioning (DR) is defined as determining new therapeutic applications for existing drugs. This approach is advantageous over de novo drug discovery in accelerating clinical development, in terms of lower costs, a shortened development period, a well-known action mechanism, a feasible dosage, and an acceptable safety profile.This work was aimed
Akihiro Ohmoto, Shigeo Fuji
openaire +2 more sources
Challenges and opportunities of drug repositioning
Trends in Pharmacological Sciences, 2013Drug repositioning is an innovation stream of pharmaceutical development that offers advantages for drug developers along with safer medicines for patients. Several drugs have been successfully repositioned to a new indication, with the most prominent of them being viagra and thalidomide, which have generated historically high revenues.
openaire +2 more sources
Repositioning Drugs: A Computational Approach
Current Drug Research ReviewsComputational drug repositioning has emerged as an efficient approach to discovering new indications for existing drugs, offering lower risk and cost compared to traditional drug discovery methods. Various computational approaches have been developed, including targetbased, gene-expression-based, phenome-based,
Bhawna Sharma +5 more
openaire +2 more sources
La Revue du praticien
DRUG REPOSITIONING. Developing new therapeutic agents ("de novo") for human diseases is an increasingly lengthy and costly process, aimed at ensuring patient safety and drug efficacy. An alternative approach, drug repurposing or repositioning, involves using already commercialized or advanced molecules.
Clémence, Réda +2 more
openaire +1 more source
DRUG REPOSITIONING. Developing new therapeutic agents ("de novo") for human diseases is an increasingly lengthy and costly process, aimed at ensuring patient safety and drug efficacy. An alternative approach, drug repurposing or repositioning, involves using already commercialized or advanced molecules.
Clémence, Réda +2 more
openaire +1 more source
2017
This chapter focuses on the basic elements of computational drug repositioning and overviews the various in silico, in vivo, and in vitro approaches. It describes the use of Systematic Drug Repositioning (SDR) technologies to predict hitherto unknown adverse drug reactions (ADRs), or to derive mechanistic explanations of known ADRs.
Spyros N. Deftereos +5 more
openaire +1 more source
This chapter focuses on the basic elements of computational drug repositioning and overviews the various in silico, in vivo, and in vitro approaches. It describes the use of Systematic Drug Repositioning (SDR) technologies to predict hitherto unknown adverse drug reactions (ADRs), or to derive mechanistic explanations of known ADRs.
Spyros N. Deftereos +5 more
openaire +1 more source
A Review of Computational Drug Repositioning Approaches
Combinatorial Chemistry & High Throughput Screening, 2018Computational drug repositioning emerges as a new idea of drug discovery and development. Contrary to conventional routines, computational drug repositioning encompasses low risk and high safety. Some successful cases demonstrated its advantage. Therefore, a large number of computational drug repositioning approaches have been developed over the past ...
Guohua, Huang +3 more
openaire +2 more sources
Drug Repositioning in the Treatment of Malaria and TB
Future Medicinal Chemistry, 2011The emergence and spread of drug resistance in the malaria parasite Plasmodium falciparum as well as multi- and extremely drug-resistant forms of Mycobacterium tuberculosis, the causative agent of TB, could hamper the control of these diseases.
Alexis, Nzila +2 more
openaire +2 more sources
Biomedical data and computational models for drug repositioning: a comprehensive review
Briefings in Bioinformatics, 2021, Mengyun Yang, Fang-Xiang Wu
exaly